Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
Lancet. 2011 Jan 1; 377(9759):31-41
All selected articles haveThis article has been added to your saved articles
You can follow/unfollow articles via MyF1000 or via the article or browse pages.
Jankowski J: F1000Prime Recommendation of [Rothwell PM et al., Lancet 2011, 377(9759):31-41]. In F1000Prime, 05 Jan 2011; DOI: 10.3410/f.7275961.7518067. F1000Prime.com/7275961#eval7518067
Choe J: F1000Prime Recommendation of [Rothwell PM et al., Lancet 2011, 377(9759):31-41]. In F1000Prime, 22 Mar 2011; DOI: 10.3410/f.7275961.9761054. F1000Prime.com/7275961#eval9761054
F1000Prime Recommendations, Dissents and Comments for [Rothwell PM et al., Lancet 2011, 377(9759):31-41]. In F1000Prime, 19 Jun 2013; F1000Prime.com/7275961
Lancet Oncol. 2010 Nov; 11(11):1066-73
James Catto and Kate Linton 10 Nov 2010
Lancet. 2012 Jan 7; 379(9810):39-46
James Catto and Kate Linton 01 Dec 2011
Lancet Oncol. 2012 Jun; 13(6):589-97
Mark Faries 17 Jul 2012
J Clin Oncol. 2010 May 1; 28(13):2181-90
Anil Vachani 09 Jun 2010
Lancet. 2009 Oct 10; 374(9697):1243-51
Susan Davis 24 Sep 2009
J Clin Oncol. 2012 Jul 1; 30(19):2334-9
BACKGROUND: Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.
METHODS: We used individual patient data from all randomised trials of daily aspirin versus no aspirin with mean duration of scheduled trial treatment of 4 years or longer to determine the effect of allocation to aspirin on risk of cancer death in relation to scheduled duration of trial treatment for gastrointestinal and non-gastrointestinal cancers. In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries.
RESULTS: In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68-0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years' follow-up (all cancers, hazard ratio [HR] 0·66, 0·50-0·87; gastrointestinal cancers, 0·46, 0·27-0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72-0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54-0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54-0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26-0·66, p=0·0001). The latent period before an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, and prostate cancer. For lung and oesophageal cancer, benefit was confined to adenocarcinomas, and the overall effect on 20-year risk of cancer death was greatest for adenocarcinomas (HR 0·66, 0·56-0·77, p<0·0001). Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age-the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42-11·74) at age 65 years and older.
INTERPRETATION: Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.
Copyright Â© 2011 Elsevier Ltd. All rights reserved.
has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000